Business
KRTL Biotech to Expand Pain Management Reach into U.S. and Global Healthcare Markets
KRTL Biotech to Expand Pain Management Reach into U.S. and Global Healthcare Markets.
About this update from Krtl Holding Group, Inc
[{"type":"text","content":"KRTL\r\nHolding Group Inc. (OTC: KRTL) (\"KRTL Holding\" or the\r\n\"Company\") today announced that its subsidiary, KRTL Biotech, Inc.,\r\nis highlighting its portfolio of pain management pharmaceuticals, one of the\r\nmost widely utilized and clinically essential categories in the Company’s\r\ninternational product portfolio.\r\nThe\r\nproduct line, developed in partnership with Industria Químico-Farmacéutica\r\nSIGMA Corp., includes both prescription and over-the-counter formulations for\r\nthe relief of acute and chronic pain, inflammation, fever, and musculoskeletal\r\ndiscomfort. These therapies serve a broad range of clinical and community\r\nhealthcare settings across Latin America.\r\n\"Pain\r\nrelief is one of the most immediate and pressing needs in global healthcare,\r\nespecially in lower-resource settings,\" said Daniel Bishop, CEO of KRTL\r\nBiotech. \"By making effective and affordable analgesics widely available,\r\nwe’re supporting functional wellness and improving quality of life.\"\r\nKey Formulations in the Pain Management Line:\r\n\r\n Analgesics\r\n and Antipyretics: Acetaminophen, Ibuprofen, Dipyrone\r\n NSAIDs: Diclofenac (oral, injectable, gel), Meloxicam, Naproxen,\r\n Ketoprofen\r\n Combination\r\n Therapies: Multimodal relief with muscle relaxants\r\n or caffeine\r\n Topical\r\n Pain Relief: Anti-inflammatory creams and gels\r\n\r\nTogether,\r\nthese options offer clinicians, pharmacists, and patients access to dependable\r\npain relief in diverse care settings.\r\nThese\r\nformulations are manufactured under certified GMP in Bolivia and are\r\ndistributed through public health systems and private retail channels across\r\nLatin America in primary care, hospitals and emergency settings. SIGMA\r\ngenerated in excess of $600,000 in revenues from these products in its fiscal\r\nyear ended March 31, 2025.\r\n\"Our\r\npain management line reflects SIGMA’s decades-long commitment to health equity\r\nin Bolivia,\" said Patricia Wilstermann, CEO of SIGMA. \"We’ve built\r\ntrust in the market through consistent product quality and\r\navailability—something we are proud to bring to KRTL’s global expansion\r\nstrategy.\"\r\nKRTL\r\nBiotech is currently evaluating regulatory entry strategies for select\r\nanalgesics and NSAIDs in the U.S., including potential alignment with the OTC\r\nMonograph system for over-t...